Unoprostone adverse effects

The use of unoprostone in the treatment of open-angle glaucoma and ocular hypertension has been reviewed (1). Most of the literature is in Japanese. The adverse effects of unoprostone are similar to those of latanoprost conjunctival hyperemia, iris pigmentation, hypertrichosis and hyperpigmentation of eyelashes, and rarely systemic effects (1). 

The success of latanoprost has stimulated development of similar prostanoids with ocular hypotensive effects, and bimatoprost, travaprost, and unoprostone are now available. These drugs act at the FP receptor and are administered as drops into the conjunctival sac once or twice daily. Adverse effects include irreversible brown pigmentation of the iris and eyelashes, drying of the eyes, and conjunctivitis. 

Unoprostone 0.15% reduces lOP somewhat less than prostaglandin analogs and requires twice-daily administration. Prostaglandin analogs are well tolerated and produce fewer systemic adverse effects than timolol. Local ocular tolerance generally is good, but ocular reactions such as punctate corneal erosions and conjunctival hyperemia do occur. Local intolerance occurs in 10% to 25% of patients with these agents. 

---